AstraZeneca Shakes Up Senior Roles Before Alexion Takeover
(Bloomberg) -- AstraZeneca Plc appointed Aradhana Sarin as chief financial officer to replace Marc Dunoyer, who will become chief executive officer of the company's Alexion Pharmaceuticals Inc. arm when the takeover is completed later this year.
Dunoyer, 68, will take on an additional new role as chief strategy officer at Astra, and will step down from its board, the U.K. drugmaker said in a statement Friday. The moves will take effect on Aug. 1 or the date the deal closes -- whichever is later.
In moves that could form part of the company's wider succession planning, Sarin, currently Alexion's CFO, will relocate from the U.S. to the U.K. She will also become an executive director, bolstering the number of women on the 12-seat board to five. Dunoyer and Sarin will report directly to CEO Pascal Soriot. Dunoyer will be responsible for developing Alexion's strategic direction and sharing Alexion's expertise across the Astra group.
The $39 billion acquisition of rare-disease specialist Alexion was first announced in December, taking some investors by surprise as it came in the midst of Astra's efforts to launch its Covid-19 vaccine. With very little crossover in portfolios, it moves Astra into a lucrative new area of medicine. The purchase of the U.S. biotech marks the largest transaction for Astra since it was founded in a 1999 combination of British and Swedish firms and entrenches its position among the world's 10 biggest drugmakers.
Astra's shares, which were little changed Friday, have more than doubled since Soriot took over in 2012. Under his leadership, the company has gone from a patent cliff-edge to an oncology powerhouse.
The company published data on Thursday that showed Lynparza, one of its key cancer drugs co-developed with Merck & Co., has shown success in early stage breast cancer treatment, reducing recurrence rates, second cancers or death by 42% for patients with the BRCA genetic mutation. The development could add $1 billion in sales for the companies, according to Sam Fazeli, a Bloomberg Intelligence analyst.
Further successes in its oncology portfolio will be a welcome development for Astra after a difficult year developing the Covid-19 vaccine with the University of Oxford. Despite providing the shot at no profit, the company has come under fire for trial missteps, supply shortages and poor communication. Astra is currently being sued by the European Union for failing to deliver the agreed number of doses this year.
With the Alexion takeover nearing completion and the initial stages of the vaccine rollout complete, questions have been raised over how long Soriot will remain at the helm. Soriot told the Financial Times last month that board planning was underway for future leadership changes and he, Chairman Leif Johansson and Dunoyer had agreed on a sequence for retiring.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.